⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VRCA News
Verrica Pharmaceuticals Inc. Common Stock
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
globenewswire.com
VRCA
2026 Assessment of Major Markets for Common Warts: Emerging Therapies Target HPV and Wart Recurrence
globenewswire.com
VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
VRCA
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
globenewswire.com
VRCA
Form 8-K
sec.gov
VRCA
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
globenewswire.com
VRCA
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
globenewswire.com
VRCA
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
globenewswire.com
VRCA
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
globenewswire.com
VRCA
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
globenewswire.com
VRCA